Výsledky vyhledávání - "Michael Rissler"

Akademický článek

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

Autor: Denis Poddubnyy, Effie Pournara, Agnieszka Zielińska, Asta Baranauskaite, Alejandro Muñoz Jiménez, Sanchayita Sadhu, Barbara Schulz, Michael Rissler, Chiara Perella, Helena Marzo-Ortega

Publikováno v: Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)

Background: This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial spondyloarthritis (axSpA) at Week 8 and up to Week 24. Methods:

Externí odkaz: https://doaj.org/article/0aab8dcaba324ec297f20dbdc50890f5

Zobrazit plný text záznamu

Akademický článek

The need for comparative data in spondyloarthritis

Autor: Ernest Choy, Xenofon Baraliakos, Frank Behrens, Salvatore D’Angelo, Kurt de Vlam, Bruce W. Kirkham, Mikkel Østergaard, Georg A. Schett, Michael Rissler, Kamel Chaouche-Teyara, Chiara Perella

Publikováno v: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-6 (2019)

Abstract Spondyloarthritis comprises a group of inflammatory diseases, characterised by inflammation within axial joints and/or peripheral arthritis, enthesitis and dactylitis. An increasing number of biologic treatments, including biosimilars, are a

Externí odkaz: https://doaj.org/article/bcfaeb54cfae4cbaa978343733a93070

Zobrazit plný text záznamu

Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results

Autor: Esteban Daudén, Aldo Cuccia, Jean-Luc Perrot, Piotr Jagiello, Ulrich Mrowietz, Matthias Augustin, Sven Gathmann, Roberto Orsenigo, Maria Polina Konstantinou, Christian Sieder, Sascha Gerdes, Külli Kingo, T. Bachhuber, Michael Rissler, Jacek C Szepietowski

Publikováno v: Journal of the European Academy of Dermatology and Venereology. 35:431-440

Introduction Psoriatic disease is associated with considerable impairment of quality of life (QoL). The PROSE study (NCT02752776) investigated the impact of secukinumab treatment on patient-reported outcomes (PRO) in patients with moderate to severe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca631fcf7f65a9b99f00f5d67986859e
https://doi.org/10.1111/jdv.16632

Zobrazit plný text záznamu

Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population

Autor: Christian Sieder, Roberto Orsenigo, Matthias Augustin, Sven Gathmann, Maria Polina Konstantinou, Ulrich Mrowietz, Sascha Gerdes, Esteban Daudén, Daniel Baeumer, Michael Rissler

Publikováno v: Journal of the European Academy of Dermatology and Venereology. 34:2548-2556

Introduction Psoriatic disease is associated with considerable impairment of Quality of Life (QoL). The PROSE study (NCT02752776) examined the impact of secukinumab on patient-reported outcomes in patients with moderate-to-severe psoriasis (PsO) stra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3682e85048fda1ec42218e7c301e4a22
https://doi.org/10.1111/jdv.16400

Zobrazit plný text záznamu

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

Autor: Chiara Perella, Michael Rissler, Asta Baranauskaite, Agnieszka Zielińska, Helena Marzo-Ortega, Barbara Schulz, Alejandro Muñoz Jiménez, Effie Pournara, Sanchayita Sadhu, Denis Poddubnyy

Publikováno v: Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Therapeutic Advances in Musculoskeletal Disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc7c5ecc1571e59bc5a0032ebbf2637
https://doaj.org/article/0aab8dcaba324ec297f20dbdc50890f5

Zobrazit plný text záznamu

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

Autor: Michael Rissler, Ulrich Mrowietz, A. David Burden, Kamel Chaouche-Teyara, Christian Sieder, Hervé Bachelez, Roberto Orsenigo

Publikováno v: Journal of the American Academy of Dermatology. 80:1344-1352

Background Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that is resistant to treatment. Secukinumab, an anti–interleukin 17A monoclonal antibody, is highly efficacious in the treatment of moderate-to-sev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f216c8d17065c745e76e82cb1f8064a6
https://doi.org/10.1016/j.jaad.2019.01.066

Zobrazit plný text záznamu

P188 Secukinumab provides significant improvement of spinal pain and lowers disease activity in patients with axial spondyloarthritis: 24-week results from a randomised controlled Phase 3b trial

Autor: Agnieszka Zielińska, Chiara Perella, Denis Poddubnyy, Effie Pournara, Sanchayita Sadhu, Barbara Schulz, Helena Marzo-Ortega, Michael Rissler, Asta Baranauskaite

Publikováno v: Rheumatology. 60

Background/Aims SKIPPAIN (NCT03136861) is the first randomised controlled study involving a biological disease-modifying anti-rheumatic drug, with a primary endpoint of spinal pain at Week 8 in patients with axial spondyloarthritis (axSpA; ankylosing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cc8d38b0d78a25e0a384fdaa856249e
https://doi.org/10.1093/rheumatology/keab247.183

Zobrazit plný text záznamu

P184 Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial

Autor: Sławomir Jeka, Barbara Schulz, Laura C. Coates, Michael Rissler, Effie Pournara, Xenofon Baraliakos, Laure Gossec, Chiara Perella, Ricardo Blanco, Salvatore D'Angelo, Georg Schett, Dermot Whyms

Publikováno v: Rheumatology. 60

Background/Aims MAXIMISE, the first randomised controlled trial evaluating efficacy of a biologic for psoriatic arthritis (PsA) axial manifestations, showed that secukinumab 300 and 150 mg provided rapid and significant improvement in ASAS20 response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::62ff692655b98d305998eaf5efe365a2
https://doi.org/10.1093/rheumatology/keab247.179

Zobrazit plný text záznamu

OP0053 SECUKINUMAB IMPROVES CLINICAL AND IMAGING OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS WITH INADEQUATE RESPONSE TO NSAIDS: WEEK 52 RESULTS FROM THE MAXIMISE TRIAL

Autor: Laure Gossec, K. Nagar, Barbara Schulz, Chiara Perella, Laura C. Coates, Salvatore D'Angelo, Georg Schett, Michael Rissler, Ricardo Blanco, Effie Pournara, Sławomir Jeka, Xenofon Baraliakos

Publikováno v: Annals of the Rheumatic Diseases. 79:35-36

Background:Although axial disease may affect up to 70% of patients (pts) with Psoriatic Arthritis (PsA), evidence on the efficacy of biologics in the treatment of axial manifestations in such pts is limited,1particularly as validated classification c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f70c8d325eeaf7e93407c497976ca6ac
https://doi.org/10.1136/annrheumdis-2020-eular.638

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání